Literature DB >> 10837438

Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome.

I Harding1, A P MacGowan, L O White, E S Darley, V Reed.   

Abstract

Logistic regression analysis was performed on data drawn from a clinical trials database for Staphylococcus aureus septicaemia treated with teicoplanin. Variables analysed were age, body weight, mean pre-dose and post-dose serum teicoplanin concentrations, mean dose (mg or mg/kg body weight) and combination versus monotherapy. Only two variables correlated with clinical outcome at a significance level better than 0.05: age (P = 0.012) and mean pre-dose serum concentration (P = 0.010). The probability of successful treatment declined with age and increased with mean pre-dose serum concentration.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837438     DOI: 10.1093/jac/45.6.835

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.

Authors:  Bernard Rouveix; François Jehl; Henri Drugeon; Ivan Brumpt; Evelyne Caulin
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

Review 3.  Current trends in the management of cardiac implantable electronic device (CIED) infections.

Authors:  Emanuele Durante-Mangoni; Irene Mattucci; Federica Agrusta; Marie-Françoise Tripodi; Riccardo Utili
Journal:  Intern Emerg Med       Date:  2012-06-29       Impact factor: 3.397

4.  The importance of a judicious and early empiric choice of antimicrobial for methicillin-resistant Staphylococcus aureus bacteraemia.

Authors:  N Shime; T Kosaka; N Fujita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-08-14       Impact factor: 3.267

5.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

Review 6.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

7.  Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.

Authors:  Takafumi Nakano; Yoshihiko Nakamura; Tohru Takata; Keiichi Irie; Kazunori Sano; Osamu Imakyure; Kenichi Mishima; Koujiro Futagami
Journal:  Int J Clin Pharm       Date:  2016-04-28

8.  Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.

Authors:  T Ueda; Y Takesue; K Nakajima; K Ichiki; A Doita; Y Wada; T Tsuchida; Y Takahashi; M Ishihara; H Ikeuchi; M Uchino; T Kimura
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-09       Impact factor: 3.267

9.  Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.

Authors:  Si-Ho Kim; Cheol-In Kang; Kyungmin Huh; Sun Young Cho; Doo Ryeon Chung; Soo-Youn Lee; Yae-Jean Kim; Kyong Ran Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-01       Impact factor: 3.267

Review 10.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.